Brain atrophy staging in spinocerebellar ataxia type 3 for clinical prognosis and trial enrichment
Open Access
- 23 December 2025
- journal article
- Published by Elsevier in EBioMedicine
- Vol. 123, 106090
Abstract
No abstract availableKeywords
Funding Information
- Alzheimerfonden
- National Institutes of Health
- ZonMw
- Biogen Inc
- National Ataxia Foundation
- State of São Paulo Research Foundation
- BrightFocus Foundation
- UCB Group
This publication has 40 references indexed in Scilit:
- Fixel‐Based Analysis of Diffusion Imaging as a Quantitative Marker of Disease State in Spinocerebellar AtaxiaAnnals of Clinical and Translational Neurology, 2025
- Antisense Oligonucleotide Silencing Reverses Abnormal Neurochemistry in Spinocerebellar Ataxia 3 MiceAnnals of Neurology, 2023
- Clinically Meaningful Magnetic Resonance Endpoints Sensitive to Preataxic Spinocerebellar Ataxia Types 1 and 3Annals of Neurology, 2022
- Digital Gait Biomarkers Allow to Capture 1‐Year Longitudinal Change in Spinocerebellar Ataxia Type 3Movement Disorders, 2022
- Regional Brain and Spinal Cord Volume Loss in Spinocerebellar Ataxia Type 3Movement Disorders, 2021
- In Vivo Molecular Signatures of Cerebellar Pathology in Spinocerebellar Ataxia Type 3Movement Disorders, 2020
- Structural signature of SCA3: From presymptomatic to late disease stagesAnnals of Neurology, 2018
- Individual changes in preclinical spinocerebellar ataxia identified via increased motor complexityMovement Disorders, 2016
- Inventory of Non-Ataxia Signs (INAS): Validation of a New Clinical Assessment InstrumentThe Cerebellum, 2012
- Evaluating the Replicability of Significance Tests for Comparing Learning Algorithms2004